Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab versus docetaxel in previously treated squamous non-small cell lung cancer
NL-OMON37458Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2012
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Pulmonary squamous cell carcinoma comparing Nivolumab with Docetaxel (2 arms). Primary endpoints: Objective response rate and Overall survival. Started Aug 2012; status: active, not recruiting.
02
Drugs
nivolumabdocetaxel
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on NL-OMON37458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37458.